Oncolytic viruses: emerging options for the treatment of breast cancer

@article{Suryawanshi2017OncolyticVE,
  title={Oncolytic viruses: emerging options for the treatment of breast cancer},
  author={Y. R. Suryawanshi and Tiantian Zhang and K. Essani},
  journal={Medical Oncology},
  year={2017},
  volume={34},
  pages={1-11}
}
  • Y. R. Suryawanshi, Tiantian Zhang, K. Essani
  • Published 2017
  • Medicine
  • Medical Oncology
  • Breast cancer (BC) is the most common type of cancer among women and is the second most common cause of cancer-related deaths, following lung cancer. Severe toxicity associated with a long-term use of BC chemo- and radiotherapy makes it essential to look for newer therapeutics. Additionally, molecular heterogeneity at both intratumoral and intertumoral levels among BC subtypes is known to result in a differential response to standard therapeutics. Oncolytic viruses (OVs) have emerged as one of… CONTINUE READING
    11 Citations

    Figures, Tables, and Topics from this paper

    The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress
    • 26
    Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy
    • 7
    • PDF
    Progress in gene therapy using oncolytic vaccinia virus as vectors
    • 6

    References

    SHOWING 1-10 OF 86 REFERENCES
    Promising oncolytic agents for metastatic breast cancer treatment
    • 9
    • PDF
    Oncolytic virotherapy of breast cancer.
    • 16
    Targeted Therapies for Brain Metastases from Breast Cancer
    • 49
    Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy
    • 38
    • Highly Influential
    • PDF
    Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    • G. Klement, Ping Huang, +5 authors R. Kerbel
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2002
    • 243
    • PDF
    Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
    • 125
    • Highly Influential
    • PDF
    Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
    • 13
    Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.
    • 47
    • Highly Influential
    Mechanisms of endocrine resistance in breast cancer.
    • 824
    • PDF